Seraxis
Carole Welsch, Ph.D., M.B.A. has a diverse range of work experience in the pharmaceutical and healthcare industries. Carole currently holds the position of Chief Business Officer at Seraxis, a role they have held since April 2016. Prior to this, they worked at Novartis Pharmaceuticals as a Medical Scientific Associate Director from August 2014 to April 2016.
Carole also has experience at QIAGEN Inc, where they held the role of Associate Director, Marketing, Personalized Healthcare from July 2012 to August 2014, and Marketing Manager, Personalized Healthcare from March 2009 to September 2012.
Before joining QIAGEN, Carole worked at Vanda Pharmaceuticals Inc., where they served as a New Product Planning Manager from September 2005 to October 2009. Carole also gained valuable experience as a Post-doctoral Research Scientist at the National Cancer Center, Singapore General Hospital, from September 2003 to August 2004.
Carole's career began at Novartis, where they worked as a Research Fellow from an unspecified start date to 2003.
Overall, Carole Welsch has a strong background in both scientific research and business management within the pharmaceutical and healthcare sectors.
Carole Welsch, Ph.D., M.B.A. pursued their education with a focus on Molecular and Cellular Biology. In 1999, they started their doctoral studies at Novartis Pharmaceuticals AG, which they successfully completed in 2002, earning their Ph.D. degree. Later, in 2004, Carole enrolled at NBS Alumni Affairs, NTU, where they obtained their Master of Business Administration (M.B.A.) degree in 2005.
This person is not in any teams
This person is not in any offices
Seraxis
Seraxis is a private biotechnology company launched in March 2013. Incorporated in Singapore and the United States, their GMP lab is located in Germantown, Maryland. Seraxis team of scientists developed novel cell and encapsulation technologies. Their main goal is to bring a practical cell therapy for insulin-dependent diabetes to the clinic andprovide a long term cure to patients that does not require the use of immuno-suppression.Their corporate structure and strategy is designed to achieve that goal as quickly as possible, while bringing maximum value to their shareholders.